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Bayesian Analysis of Evidence from Studies of Warfarin v Aspirin 
for Symptomatic Intracranial Stenosis 
 
Vicki Hertzberg Barney Stern Karen Johnston 
Emory University University of Maryland University of Virginia 
 
 
Bayesian analyses of symptomatic intracranial stenosis studies were conducted to compare the benefits of 
long-term therapy with warfarin to aspirin. The synthesis of evidence of effect from previous non-
randomized studies in monitoring a randomized clinical trial was of particular interest. Sequential 
Bayesian learning analysis was conducted and Bayesian hierarchical random effects models were used to 
incorporate variability between studies. The posterior point estimates for the risk rate ratio (RRR) were 
similar between analyses, although the interval estimates resulting from the hierarchical analyses are 
larger than the corresponding Bayesian learning analyses. This demonstrated the difference between these 
methods in accounting for between-study variability. This study suggests that Bayesian synthesis can be a 
useful supplement to futility analysis in the process of monitoring randomized clinical trials. 
 
Key words: Bayesian analysis, Bayesian hierarchical model, Bayesian learning, randomized clinical trial, 
epidemiology, stroke. 
 
 
Introduction 
A responsibility of the committees charged with 
monitoring randomized clinical trials is to track 
new evidence from similar studies. However, 
there are no specific guidelines for the assembly 
and analysis of such information. Recently the 
use of Bayesian methods has become accepted 
in the randomized clinical trials (RCT) 
community. (Berry, Berry, McKellar & Pearson, 
2003). One area in which Bayesian methods are 
useful is in the synthesis of evidence. 
(Spiegelhalter, Abrams & Myles, 2004) Thus 
such methods could provide a data safety 
committee with useful insights into relevant 
external information accumulating during the 
course of a study. 
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Although Bayesian methods are 
growing in acceptance in the RCT community, 
their use in stroke RCTs is still debated (Berry 
2005, Donnan, Davis & Ludbrook, 2005; 
Howard, Coffey & Cutter, 2005; Krams, Lees & 
Berry, 2005). This study explores the use of two 
Bayesian techniques for synthesis of evidence. 
Specifically sequential Bayesian learning and 
hierarchical Bayesian models are used (Gelman, 
Carlin, Stern & Rubin, 2004) to examine results 
from accumulating studies, then illustrate their 
application to the Warfarin v Aspirin for 
Symptomatic Intracranial Disease (WASID) 
trial. 
 
WASID Background 
A long-standing secondary stroke 
prevention strategy for patients with 
symptomatic intracranial atherostenosis has been 
warfarin therapy. Warfarin’s use was predicated 
on evidence published in a case series from the 
Mayo Clinic in the 1950’s (Millikan, Siekert & 
Shick, 1954). This finding was subsequently 
supported by similarly positive results in 
observational studies (Marzewski, et al,. 1982; 
Moufarrij, Little, Furlan, Williams & 
Marzewski, 1984; Chimowitz, et al., 1995; Thijs 
& Albers, 2000; Qureshi, et al., 2003) 
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In 1998, the National Institute of 
Neurological Diseases and Stroke (NINDS) 
funded the Warfarin vs Aspirin for Symptomatic 
Intracranial Disease (WASID) study, the first 
double-blinded, placebo-controlled randomized 
clinical trial (RCT) to test the superiority of 
warfarin (International Normalized Ratio [INR] 
2 – 3) over high-dose aspirin (650 mg twice 
daily) in this patient population. The protocol 
called for enrollment of 806 patients with 
angiographically proven symptomatic 
intracranial disease to determine a combined 
endpoint of stroke (ischemic and hemorrhagic) 
and vascular death. The sample size was chosen 
to give 80% power to detect a difference 
between event rates of 33% in the aspirin group 
compared to 22% in the warfarin group over 3 
years after, accounting for a 24% rate of 
discontinuation of study medications and 1% 
loss to follow-up, which translates to an 
alternative hazard ratio (HR) of 1.47. 
In July, 2003, after 569 patients were 
enrolled, NINDS, acting upon advice from the 
WASID Performance and Safety Monitoring 
Board (PSMB), stopped WASID because 
subjects randomized to warfarin were at 
significant increased risk of major non-endpoint 
adverse events and the potential for a benefit in 
primary endpoint events that was sufficient to 
outweigh these adverse events was very low. 
Indeed, after study closeout, there was no 
advantage of warfarin versus aspirin (HR = 1.04; 
95% CI = 0.73 to 1.48) (Chimowitz, et al., 
2005). 
 
Description of Prior Evidence 
Existing literature on warfarin treatment 
for intracranial stenosis was reviewed (Millikan, 
et al., 1954; Marzewski, et al., 1982; Moufarrij, 
et al., 1984; Chimowitz, et al., 1995; Thijs, et al., 
2000; Qureshi, et al., 2003). Of the six 
publications, two studies (Marzewski, et al., 
1982; Moufarrij, et al., 1984) insufficiently 
detailed; focus is placed on the remaining four 
publications in addition to the article describing 
the WASID trial results (Chimowitz, et al. 
2005). (Relevant features of these studies, along 
with pertinent effect estimates, are summarized 
in Table 1.) 
Study 1: Millikan, et al. (1954) 
examined Mayo Clinic patients with either 
intermittent insufficiency of the basilar system 
or thrombosis within the basilar arterial system. 
They found that 10/23 (43%) of patients who did 
not receive anticoagulant therapy died, 
compared to 3/21 (14%) of patients receiving 
anticoagulants. The estimated odds ratio (OR) 
for death comparing aspirin to warfarin (with 
associated 95% confidence interval [CI]) is 4.62 
(2.18, 9.79). 
Study 2: Chimowitz, et al. (1995) 
assessed cases with symptomatic, 
angiographically confirmed stenosis (≥ 50%) of 
a major intracranial artery in a retrospective, 
non-randomized cohort study. Of the 151 
patients included in the study, 88 were treated 
with warfarin and 63 were treated with aspirin. 
Treatments and dosages were chosen by local 
physician. Patients were followed by chart 
review and telephone or personal / next-of-kin 
interview until first occurrence of a primary 
endpoint (major vascular event defined as 
ischemic stroke, myocardial infarction or sudden 
death), change in therapy (from aspirin to 
warfarin or vice versa), or last contact or death 
due to non-vascular cause. Warfarin patients 
were followed for a median duration of 14.7 
months, experiencing 8.4 major vascular events 
per 100 patient years of follow-up. Aspirin 
patients were followed for a median duration of 
19.3 months, experiencing 18.1 major vascular 
events per 100 patient years. The estimate of 
relative risk (RR) of major vascular events in 
aspirin patients compared to warfarin patients is 
2.2 (95% CI, 1.2, 4.4). 
Study 3: Thijs and Albers (2000) 
interviewed 51 patients identified from chart 
review. All patients had symptomatic 
intracranial stenosis and had failed 
antithrombotic therapy. Of these, 32 patients 
were followed on warfarin and 19 on aspirin. 
Cox proportional hazards analysis was 
conducted to estimate the hazard ratio (HR) for 
cerebral ischemic events (including TIA) after 
adjusting for age, presence of anterior 
circulation disease, Caucasian race, and 
hyperlipidemia. The estimated aspirin to 
warfarin HR is 4.9 (95% CI, 1.7, 13.9). 
Study 4: Qureshi, et al. (2003) 
retrospectively assessed 102 patients with 
symptomatic vertebrobasilar stenosis. Cox 
proportional hazards analysis gave an estimated  
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HR of 55.6 (95% CI, 9.1, 333), comparing 
stroke free survival for patients receiving either 
warfarin or aspirin to patients receiving neither 
after adjustment for sex, race, hypertension, 
diabetes mellitus, cigarette smoking, 
hyperlipidemia, and lesion location. Additional 
data provided by the authors (Table 2) allowed 
calculation of the aspirin to warfarin HR as 0.63 
(95% CI, 0.25, 1.59). 
Study 5: Chimowitz, et al. (2005) was 
the only RCT comparing warfarin to aspirin in 
patients with this disease. 569 patients were 
followed for an average of 1.8 years. The aspirin 
to warfarin HR is 1.04 (95% CI, 0.74, 1.49). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Endpoints (Stroke or Death) in 
Qureshi, et al. (2003)* 
 Warfarin Aspirin 
 (n=46) (n =40) 
Number of Patients 46 40 
Stroke or Death 10 8 
Person-Months to 
Endpoint 619 787 
*Qureshi & Suri, personal communication, 
December 22, 2005 
Table 1: Data Used in Study Analyses 
Study 
Number & 
Author(s) 
Year Endpoint 
Warfarin: 
#events/ 
#observations 
Aspirin: 
#events/ 
#observations 
Aspirin/Warfarin 
ratio (95% CI) 
Log(ratio) 
and (sd) Caveat* 
(1) 
Millikan, 
et al. 
1954 Death 3 / 21 patients 10 / 23 patients 4.62 (2.18, 9.79) 1.53 (0.75) A 
(2) 
Chimowitz, 
et al. 
1995 Stroke, MI, sudden death 
26 / 143 
patient-year 
14 / 166 patient-
year 2.17 (1.16, 4.35) 0.63 (0.33) B 
(3) 
Thijs and 
Albers 
2000 
Cerebral 
ischemic 
events 
Not given Not given 4.9 (1.7, 13.9) 0.77 (0.33) C 
(4) 
Qureshi, 
et al. 
2003 Stroke or death 
10 / 619 
patient-month 
8 / 787 patient-
month 0.63 (0.25, 1.59) -0.46 (0.47) D 
(5) 
Chimowitz, 
et al. 
2005 
Ischemic 
stroke, brain 
hemorrhage, 
vascular 
death 
62 / 504.4 
patient-year 
63 / 541.7 
patient-year 1.04 (0.73, 1.48) 0.06 (0.18)  
Caveats: 
A: The treatment received by patients not receiving warfarin is unclear as are the inclusion criteria 
B: Retrospective study possibly subject to selection bias 
C: HRR is adjusted for age, presence of anterior circulation disease, Caucasian race, hyperlipidemia 
D: Unpublished result from data supporting paper; Qureshi & Suri, personal communication, December 22, 2005 
BAYESIAN ANALYSIS OF WARFARIN V ASPIRIN FOR INTRACRANIAL STENOSIS 
586 
 
Methodology 
Bayesian Learning 
Because the results of these studies were 
accumulated over 50 years, a Bayesian learning 
approach was first used in which the posterior 
distribution derived from the analysis of the 
oldest result was used as the prior distribution in 
order to derive the posterior distribution with the 
next study. The goal was to estimate the 
posterior distribution of θ, the unknown mean of 
the distribution of log(RRR) from its prior and 
the preceding study results with the posterior 
distribution derived from study i-1 serving as the 
prior distribution for study i for i = 2,…5. This is 
expressed as follows: 
Let Yi = log(RRRi). 
 
Assuming that Yi is a realization from a random 
distribution depending on θ, the Bayes theorem 
gives 
f(θ|Y1) ∝ f(Y1| θ) × f(θ),                (1) 
 
f(θ|Y2) ∝ f(Y2| θ) × f(θ|Y1).             (2) 
 
In general f(θ|Yi) ∝ f(Yi| θ) × f(θ|Yi-1), where 
f(θ) is the baseline prior distribution for θ and i > 
1, assuming that log(RRR) is normally 
distributed, using the normal distribution for the 
likelihood and its conjugate, the normal 
distribution, as the prior for θ. 
 
Hierarchical Random Effects Models 
A simultaneous analysis in a 
hierarchical random effects model was also 
considered, specifically each has an estimate Yi 
of a treatment effect θi, such that: 
 
Yi ~ f(yi | θi).                         (3) 
 
These treatment effects are treated as 
realizations of random variables from the same 
population, that is, 
 
θi ~ f(θi | θµ),                         (4) 
 
with θµ having its own prior distribution f(θµ). 
Because all of the studies present an 
estimate of risk which, after transformation, has 
a normal distribution, a normal distribution was 
used for functional forms of likelihood and prior 
distribution functions. For some studies the 
results may also be viewed as events per person-
years of observation per group. In this case 
Poisson hierarchical models can be used as 
follows: 
 
For group j in study i let the number of 
events, Eij ~ Poiss (nij × exp(φxj + εij)), 
where xj is an indicator variable denoting 
aspirin group membership, εij ~ N(0, σ2ε) 
and φ ~ N(0, σ2φ). Here nij, the number of 
person years at risk, is an offset term and φ 
is the population value for log(RRR). 
 
For each of these analyses a posterior mean was 
generated with 95% Bayes interval and posterior 
median with 50% Bayes interval or inter-quartile 
range. 
For each analysis three different 
baseline priors were used as follows: 
1) θ ~ N(0, 10) (a weakly non-informative 
prior; warfarin has no effect); 
2) θ ~ N(0, 0.5) (a skeptical prior; warfarin 
has no effect); 
3) θ ~ N(0.5, 10) (an enthusiastic prior; 
warfarin reduces risk by 40%).  
Additional sensitivity analyses included only 
studies 2, 4 and 5. 
As the Bayesian learning analysis 
proceeded, graphs of the posterior, likelihood 
and prior functions were inspected at each step. 
Thus, the relative influence that the likelihood 
and prior exerted in determination of the 
resulting posterior was able to be determined. 
 
Numerical Methods 
In addition to the distributions for the 
parameters of interest, non-informative prior 
distributions were placed on any nuisance 
parameters (e.g., σ2ε in the hierarchical Poisson 
model) then integrated over these parameters in 
the posterior distribution. For estimation, Gibbs 
sampling (Casella & George, 1992) was used as 
performed in the WinBUGS software 
(Spiegelhalter, Thomas, Best, Gilks & Lunn, 
2003). Convergence was monitored using the 
scale reduction factor (SRF) (Gelman, et al., 
2004). For each model analyzed, 3 chains were 
run with 1,000 iterations each (discarding the 
first 500 in each chain). For analyses which 
resulted in SRF > 1.1 the number of iterations 
was increased in each chain by a factor of 10 the 
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program run again until the SRF ≤ 1.1. Note that 
such increases were only necessary for analysis 
of the hierarchical random effects Poisson 
models. 
 
Results 
Bayesian Learning Analyses 
The results of the sequential Bayesian 
learning analysis with log(RRR) as a normal 
variate using studies 1-4 are shown in Table 3. 
Note that the Bayesian results that were 
available at the time that WASID began (studies 
1 and 2) were mixed in their support for an 
effect of warfarin as hypothesized for the 
WASID clinical trial, i.e., RRR = .33 / .22 = 1.5, 
versus the null hypothesis RRR = 1.  
Specifically, although the 95% Bayes 
intervals based on the initial informative prior or 
the initial enthusiastic prior include 1.5 but 
exclude 1, the interval based on the initial 
skeptical prior includes both values. With the 
subsequent addition of study 3’s results the 
evidence favoring warfarin grew stronger. The 
95% Bayes intervals stemming from both initial 
skeptical and initial enthusiastic priors now 
include 1.5 but exclude 1. Moreover the interval 
stemming from the initial non-informative prior 
excludes both 1 and 1.5 to the left. Addition of 
study 4 has little effect on point and interval  
estimates. Further point estimates stemming  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
from the non-informative prior tend to be much 
higher than corresponding point estimates 
stemming from skeptical and enthusiastic priors 
at each point. This disparity is due to the 
difference in variance between the non-
informative prior versus skeptical and 
enthusiastic priors. 
A hypothetical future study of warfarin 
and aspirin would incorporate the results of 
study 5. With this addition, note that interval 
estimates stemming from initial non-informative 
and skeptical priors now include 1. Indeed, the 
Bayes interval from the initial skeptical prior 
now excludes 1.5 to the right. The Bayes 
interval stemming from the enthusiastic prior 
excludes 1 but covers 1.5 (the alternative 
hypothesis for WASID) and 2. 
Sensitivity analyses including only 
studies 2, 4 and 5 result in posterior point and 
interval estimates that are not much different 
after adding study 4 into the analysis, especially 
with the skeptical and enthusiastic priors (Table 
4). The results after introduction of only study 2 
are like the results after inclusion of both studies 
1 and 2, suggesting that the optimistic estimates 
from study 1 do not contribute substantially to 
the overall conclusion. Additional sensitivity 
analysis including study 4 produced posterior 
point and interval estimates that were virtually 
identical suggesting that study 4 does not have a 
substantial impact on the analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Posterior Point and Interval Estimates for θ = RRR from Bayesian Learning Analysis Using All Studies 
Study 
Added Interval Type Non-Informative Prior Skeptical Prior Enthusiastic Prior 
1 
Mean θ (95% Bayes interval) 4.48 (1.14, 17.64) 1.11 (0.75, 1.63) 1.82 (1.23, 2.69) 
Median θ (50% Bayes interval) 4.48 (2.72, 7.39) 1.22 (1.0, 1.35) 1.82 (1.49, 2.23) 
2 
Mean θ (95% Bayes interval) 2.46 (1.36, 4.44) 1.35 (0.91, 1.99) 1.82 (1.23, 2.69) 
Median θ (50% Bayes interval) 2.46 (2.01, 3.00) 1.35 (1.22, 1.49) 1.82 (1.65, 2.01) 
3 
Mean θ (95% Bayes interval) 3.00 (1.67, 5.42) 1.65 (1.12, 2.44) 2.01 (1.36, 2.97) 
Median θ (50% Bayes interval) 3.00 (2.46, 3.67) 1.65 (1.49, 1.82) 2.01 (1.82, 2.46) 
4 
Mean θ (95% Bayes interval) 2.72 (1.65, 4.95) 1.65 (1.11, 2.46) 2.01 (1.35, 3.00) 
Median θ (50% Bayes interval) 2.72 (2.23, 3.32) 1.65 (1.49, 1.82) 2.01 (1.82, 2.23) 
5 
Mean θ (95% Bayes interval) 1.35 (1.00, 2.01) 1.35 (1.00, 1.43) 1.49 (1.11, 2.01) 
Median θ (50% Bayes interval) 1.49 (1.22, 1.65) 1.35 (1.22, 1.49) 1.49 (1.35, 1.65) 
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Simultaneous Analysis of RRR Using 
Hierarchical Random Effects Models with the 
Normal Distribution 
The simultaneous analysis of these 
studies was examined in the normal model for 
log(RRR). Posterior point and interval estimates 
for the analyses of various subsets of studies are 
shown in Table 5. The results are very similar to 
the results of the comparable Bayesian learning 
analysis, although with wider intervals, 
indicating different consequences of the ways 
these methods address variability between 
studies. Specifically the Bayesian learning 
analysis provides for a posterior variance 
estimate at each step, but this estimate can drift 
between steps. In comparison, the simultaneous 
nature of the hierarchical models requires 
adjustment over all studies at once. 
 
Simultaneous Analysis of RRR Using 
Hierarchical Random Effects with the Poisson 
Distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The HR from a Poisson model that 
compares events per person year between 
thegroups was examined, with interest in the 
ratio between the two Poisson parameters, which 
are an estimate of RRR. Since not all studies 
were sufficiently detailed in their report of rates, 
these analyses are limited. Nevertheless the 
extent of knowledge for 3 of the existing studies 
and subsets was examined. 
The results of these analyses are shown 
in Table 6. The first analysis, using only study 2, 
represents a simple Bayesian analysis using a 
Poisson distribution. Note that the value of 1.5 is 
included in the 95% Bayes interval estimates, 
while the null value 1.0 is excluded by the 
analysis using the non-informative and 
enthusiastic priors. The other two analyses used 
a hierarchical random effects Poisson model to 
adjust for differences between studies. In these 
analyses using studies 2 and 4 or using studies 2, 
4, and 5, the 95% Bayes interval estimates 
include both 1 and 1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Posterior Point and Interval Estimates for θ = RRR from Bayesian Learning Analysis Using 
Restricted Set of Studies 
Study 
Added Interval Type 
Non-Informative 
Prior Skeptical Prior Enthusiastic Prior 
2 
Mean θ (95% Bayes interval) 2.23 (1.23, 4.01) 1.35 (0.91, 1.99) 1.82 (1.23, 2.69) 
Median θ (50% Bayes interval) 2.23 (1.82, 2.72) 1.35 (1.22, 1.65) 1.82 (1.65, 2.01) 
4 
Mean θ (95% Bayes interval) 2.01 (1.22, 3.67) 1.35 (0.90, 2.01) 1.82 (1.22, 2.72) 
Median θ (50% Bayes interval) 2.23 (1.82, 2.46) 1.35 (1.22, 1.49) 1.82 (1.65, 2.01) 
5 
Mean θ (95% Bayes interval) 1.35 (0.90, 1.82) 1.22 (0.90, 1.65) 1.35 (1.11, 1.82) 
Median θ (50% Bayes interval) 1.35 (1.11, 1.49) 1.22 (1.11, 1.35) 1.35 (1.22, 1.49) 
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Conclusion 
Reconciliation of the results of WASID with 
previous reports of a strong effect of warfarin is 
difficult. Many would advocate that the biases of 
the prior observational studies should discount 
those results in favor of the unbiased result of 
the RCT. Certainly the use of randomization, 
blinding, standardization of patient management 
protocols, and central endpoint adjudication 
ensure bias-free estimate of treatment effect 
from the RCT. However, RCTs are not without 
other sources of bias stemming from the 
selection of participating physicians and clinics 
as well as the enrollment of consenting patients. 
Thus, a growing community of investigators 
(Berry, et al., 2003; Brophy & Lawrence, 1995; 
Diamond & Kaul, 2004) advocates the use of 
Bayesian statistical methods to interpret results 
of clinical trials as well as to synthesize 
evidence from a set of studies about the effect of 
treatment(s). Bayesian statistical methods have 
recently gained notice in the arena of stroke 
clinical trials (Berry, 2005; Donnan, et al., 2005; 
Howard, et al., 2005; Krams, et al., 2005). 
Although taken as a single trial the 
WASID results would seem to extinguish the 
utility of warfarin as a secondary prevention 
strategy for patients with symptomatic 
intracranial stenosis, some  have  not  been  so  
quick  to   proclaim 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
warfarin’s demise (Koroshetz, 2005). In this 
presentation we explore application of Bayesian 
methods to interpret the WASID results in light 
of the overall accumulation of evidence 
regarding the effect of warfarin and consider 
what insights the Bayesian analyses might have 
indicated along the way? 
At the time of the WASID proposal 
submission, the accumulated evidence taken 
from the Bayesian learning perspective fit neatly 
with the standard of equipoise necessary to 
justify NIH funding. Specifically, those coming 
to the debate with no or vague prior beliefs (i.e., 
the non-informative prior) as well as those 
favoring warfarin (i.e., the enthusiast) could 
justify RRR = 1.5 and exclude RRR = 1. On the 
other hand, those coming to the problem 
favoring no difference (i.e., the skeptic) could 
justify both values for RRR. With the 
hierarchical analyses the alignments of skeptics 
and enthusiasts remain the same, while those 
with vague beliefs now align with the skeptics. 
In July 2003, when the study was 
terminated for safety reasons, the results of the 
Bayesian learning analyses all excluded RRR = 
1 from interval estimates, regardless of prior 
beliefs. When the analysis is restricted to studies 
meeting perceived quality criteria, the initial 
state of equipoise described above remained. 
Table 5: Posterior Point and Interval estimates for θ = RRR Using Hierarchical Random Effects Model 
with Normal Distribution 
Studies 
Included Interval Type 
Non-Informative 
Prior Skeptical Prior Enthusiastic Prior 
1, 2, 3, 4 
Mean θ (95% Bayes interval) 2.72 (0.27, 14.88) 1.11 (0.67, 1.82) 1.82 (1.22, 3.00) 
Median θ (50% Bayes interval) 3.00 (2.01, 4.06) 1.11 (1.00, 1.35) 1.82 (1.65, 2.23) 
1, 2, 3, 
4, 5 
Mean θ (95% Bayes interval) 2.01 (0.55, 6.69) 1.22 (0.74, 1.82) 1.82 (1.22, 2.72) 
Median θ (50% Bayes interval) 2.01 (1.49, 2.72) 1.22 (1.00, 1.35) 1.82 (1.49, 2.01) 
2, 4 
Mean θ (95% Bayes interval) 1.49 (0, 4.9 x 105) 1.00 (0.67, 1.65) 1.65 (1.00, 2.72) 
Median θ (50% Bayes interval) 1.82 (0.27, 7.39) 1.00 (0.90, 1.22) 1.65 (1.35, 2.01) 
2, 4, 5 
Mean θ (95% Bayes interval) 1.22 (0.07, 20.1) 1.11 (0.67, 1.65) 1.49 (1.11, 2.46) 
Median θ (50% Bayes interval) 1.35 (0.90, 2.01) 1.11 (1.00, 1.22) 1.49 (1.35, 1.82) 
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Moreover, the hierarchical analyses limited to 
published results as of July 2003 would be no 
different than before. However, the inclusion of 
the rates from study 4, if they had been 
published at that time, leads to hierarchical 
model results that lend support for both 
RRR=1.5 or RRR=1 regardless of prior belief. 
The lack of strict correspondence between 
conclusions from Bayesian learning with those 
from Bayesian hierarchical random effects 
models results from differences between 
methods in incorporating between-study 
variability. The studies do have differences in 
design (sample size, endpoint definitions and 
inclusion criteria) warranting allowances in the 
modeling process. Although none of studies 1-4 
were randomized clinical trials, hierarchical 
models can be extended to adjust for different 
classes (such as RCTs versus non-randomized 
studies) when 2 or more studies of each class are 
present. Unfortunately only one RCT was 
available to include. 
It is particularly interesting to note the 
change in conclusions wrought by the 
unpublished, negative result of Study 4. This 
finding reinforces the importance of finding all 
results, even negative ones, in compiling 
evidence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ability to generate interval estimates 
and use differing priors deepens understanding 
of the current evidence in light of previous 
studies. These results point to the utility of 
Bayesian analyses of prior studies as an 
additional tool for monitoring clinical trials. The 
concordance of frequentist and Bayesian 
efficacy analyses would provide robust 
confirmation of the appropriateness of a futility 
analysis when decisions regarding the 
continuation or stopping of a clinical trial are 
made. 
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Table 6: Posterior Point and Interval estimates for φ = RRR Using Hierarchical Random Effects Model with 
Poisson Distribution 
Studies 
Included Interval Type 
Non-Informative 
Prior Skeptical Prior Enthusiastic Prior 
2* 
Mean φ (95% Bayes interval) 2.23 (1.22, 4.48) 1.65 (1.0, 3.0) 2.01 (1.22, 3.32) 
Median φ (50% Bayes interval) 2.23 (1.82, 2.72) 1.82 (1.49, 2.01) 2.01 (1.65, 2.46) 
2, 4 
Mean φ (95% Bayes interval) 0.41 (0, 54200) 1.0 (0.41, 2.72) 1.65 (0.67, 4.48) 
Median φ (50% Bayes interval) 0.41 (0.01, 22.20) 1.0 (0.74. 1.35) 1.65 (1.22, 2.23) 
2, 4, 5 
Mean φ (95% Bayes interval) 1.11 (0, 24300) 1.0 (0.41, 2.72) 1.65 (0.55, 4.48) 
Median φ (50% Bayes interval) 1.11 (0.03, 54.6) 1.0 (0.74, 1.35) 1.65 (1.11, 2.23) 
*Uses simple Poisson model for two groups 
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